BIOPHARMA CREDIT PLC

1. BIOPHARMA CREDIT PLC 2017-02-06 → present
2. PRECIS (2772) PLC 2016-10-24 → 2017-02-06

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

IFRS

Reporting scope

Consolidated group

Auditor

Ernst & Young LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The Directors consider that it is appropriate to adopt the going concern basis in preparing the financial statements. After making enquiries, and bearing in mind the nature of the Company’s business and assets, the Directors consider that the Company has adequate resources to continue operating for the foreseeable future, being a period of at least 12 months from the date that these financial statements were approved.”

Group structure

1. BIOPHARMA CREDIT PLC · parent
   1. BPCR Ondogaps Limited 100% · England and Wales
   2. BPCR GP Limited 100% · England and Wales
   3. LumiraDx Colombia Holdings Limited 41% · UK

Significant events

• “From 8 January 2025 to 21 March 2025, the Company repurchased 46,260,732 shares. The Company currently holds 234,136,142 of its ordinary shares in treasury and has 1,139,795,925 ordinary shares in issue (excluding treasury shares).”
• “On 23 January 2025, the Board approved an interim dividend in respect of the financial period ending 31 December 2024 of $0.0289309 per ordinary share, that was paid on 28 February 2025.”
• “On 5 March 2025, the Company purchased $15,000,000 of 0.75 per cent. senior unsecured convertible notes due 2030 issued by Alphaeon Holdings, Inc.”
• “On 19 March 2025, the Company notes the announcement by Paratek Pharmaceuticals ("Paratek") regarding the definitive agreement pursuant to which Paratek will acquire OptiNose US ("OptiNose") for up to $185,000,000. The Company has a $71,500,000 investment in a senior secured loan to OptiNose, out of a total $130,000,000 senior secured loan, which would be prepaid at the closing of the transaction.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

16

last 12 months

Capital events

13

last 24 months

Officers appointed

1

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  —

  Not reported

• Cash

  -95.8%

  £100,113,417 → £4,166,049

• Net assets

  -11.9%

  £993,966,642 → £875,965,901

• Employees

  —

  Not reported

• Profit before tax

  +12.7%

  £80,392,884 → £90,637,509

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers